Richmond, CA / Frankfurt, September 16, 2008 – Nanostart holding Lumiphore announced the appointment of Dr. David J. Ecker to its board of directors. Dr. Ecker is Chief Scientific Officer and a founder of Ibis Biosciences. He is also a co-founder and Vice President of Isis Pharmaceuticals. As the third member of Lumiphore's board, he brings both a general expertise in successful biotech commercialization and a specific expertise in detection and assay platforms.
Dr. Ecker has over 24 years of experience in the pharmaceutical/biotechnology industry in cancer and infectious disease research and development. He was a primary inventor of the Ibis T5000 biosensor technology, which is a revolutionary new platform for the identification of infectious diseases. Prior to Isis, Dr. Ecker was Assistant Director, Department of Molecular Genetics at SmithKline and French Laboratories (now GlaxoSmithKline) where he focused on applications of molecular biology to drug discovery. Dr. Ecker has published extensively in fields that include biosensor technology, infectious disease research, biodefense, biochemistry, gene construction and expression. He has authored more than 80 scientific publications and over 50 U.S. patents. Dr. Ecker received his Ph.D. in chemistry and biochemistry from Utah State University and was an American Cancer Society Fellow in chemistry at the University of California, Berkeley.
About Lumiphore:
Based in Richmond, California, Lumiphore is a biotechnology company developing proprietary fluorescent-metal lanthanide technology for use in high-value applications and commercializing the technology by entering into market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. Metal lanthanide reporters provide increased sensitivity for fluorescent reagents in biology, since they make possible time-resolved detection vastly improving assay signals over background noise. For more information about Lumiphore, log onto www.lumiphore.com Lumi4TM is a trademark of Lumiphore, Inc.
About Nanostart:
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de. Disclaimer: This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
